Pharma Connect Capital invests in MimeCure

We’re excited to announce that Pharma Connect Capital has invested in MimeCure to propel our COPD treatment research forward. Pharma Connect Capital is a regional investment fund focused on supporting innovative pharmaceutical companies in the Northern Netherlands, backed by key partners such as Investerings Fonds Groningen, Hanzeborg BV (UMCG), NV NOM, Ir. G.J. Smid Fonds, and RUG Ventures. Their commitment to groundbreaking medical solutions aligns with our mission to offer new hope for COPD patients. With this investment, we’re moving closer to delivering a potentially curative therapy for COPD.